Aurobindo subsidiary Eugia gets FDA approval for Cyclophosphamide Injection

TAGS

Aurobindo Pharma said that its subsidiary Eugia Pharma Specialities has secured approval from the US Food and Drug Administration () for the new drug application for its 500 mg/2.5 mL and 1 g/5 mL vials.

Cyclophosphamide Injection is indicated in the US for malignant lymphomas, , neuroblastoma, adenocarcinoma of the ovary, retinoblastoma, leukemias, mycosis fungoides, and carcinoma of the breast.

See also  Hemogenyx Pharmaceuticals receives FDA nod for HEMO-CAR-T AML treatment study

The Indian pharma company said that the drug will be available in ready-to-use (RTU) injection preparation. It will be rolled out in the near term in the and will be manufactured at Eugia Pharma Specialities’ facility in India.

According to IQVIA, cyclophosphamide has an addressable market size of $170 million for the 12 months ending June 2021.

See also  Carrington Farms acquires organic whey protein brand tera'swhey

Cyclophosphamide Injection is the 19th product for to be approved for Eugia Pharma Specialities, while taking Aurobindo Pharma’s ANDA approvals from the FDA to 482.


Discover more from Business-News-Today.com

Subscribe to get the latest posts sent to your email.

CATEGORIES
TAGS
Share This